PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
12.15%
Revenue growth below 50% of VET's 27.71%. Michael Burry would check for competitive disadvantage risks.
16.28%
Cost growth less than half of VET's 141.31%. David Dodd would verify if cost advantage is structural.
9.37%
Gross profit growth exceeding 1.5x VET's 5.64%. David Dodd would verify competitive advantages.
-2.47%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.25%
Other expenses growth less than half of VET's 88.53%. David Dodd would verify if advantage is sustainable.
19.00%
Operating expenses growth above 1.5x VET's 1.21%. Michael Burry would check for inefficiency.
17.29%
Total costs growth less than half of VET's 46.75%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-0.85%
D&A reduction while VET shows 10.94% growth. Joel Greenblatt would examine efficiency.
-38.64%
EBITDA decline while VET shows 9.41% growth. Joel Greenblatt would examine position.
16.43%
EBITDA margin growth while VET declines. John Neff would investigate advantages.
3.15%
Operating income growth below 50% of VET's 8.63%. Michael Burry would check for structural issues.
-8.02%
Both companies show margin pressure. Martin Whitman would check industry conditions.
96.83%
Other expenses growth 1.1-1.25x VET's 80.18%. Bill Ackman would demand expense justification.
-63.39%
Pre-tax income decline while VET shows 58.80% growth. Joel Greenblatt would examine position.
-67.36%
Pre-tax margin decline while VET shows 24.35% growth. Joel Greenblatt would examine position.
-55.53%
Tax expense reduction while VET shows 80.96% growth. Joel Greenblatt would examine advantage.
-68.39%
Net income decline while VET shows 57.72% growth. Joel Greenblatt would examine position.
-71.81%
Net margin decline while VET shows 23.50% growth. Joel Greenblatt would examine position.
-67.71%
EPS decline while VET shows 52.83% growth. Joel Greenblatt would examine position.
-68.09%
Diluted EPS decline while VET shows 49.06% growth. Joel Greenblatt would examine position.
-1.94%
Share count reduction while VET shows 0.89% change. Joel Greenblatt would examine strategy.
-1.81%
Diluted share reduction while VET shows 1.92% change. Joel Greenblatt would examine strategy.